Section Arrow
RYTM.NASDAQ
- Rhythm Pharmaceuticals
Quotes are at least 15-min delayed:2025/12/17 06:31 EST
Pre Market
Last
 112.2
-0.25 (-0.22%)
Bid
111.46
Ask
135.99
High 112.81 
Low 111.5 
Volume 221 
Regular Hours (Closed)
Last
 112.45
-0.07 (-0.06%)
Day High 
114.4635 
Prev. Close
112.52 
1-M High
122.2 
Volume 
1.11M 
Bid
111.46
Ask
135.99
Day Low
111.37 
Open
111.41 
1-M Low
98.52 
Market Cap 
7.51B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 107.07 
20-SMA 105.72 
50-SMA 105.41 
52-W High 122.2 
52-W Low 45.905 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.10/-2.59
Enterprise Value
7.51B
Balance Sheet
Book Value Per Share
2.23
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
130.13M
Operating Revenue Per Share
0.66
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RZLTRezolute2.02+0.39+23.93%-- 
Pre Market 1.98 -0.04 -1.98%
IBRXImmunityBio2.16-0.06-2.70%-- 
Pre Market 2.19 +0.03 +1.39%
ROIVRoivant Sciences Ltd22.94+1.04+4.75%1.95PE
Pre Market 23.55 +0.61 +2.66%
IOVAIovance Biotherapeutics2.25+0.09+4.17%-- 
Pre Market 2.25 0 0.00%
MISTMilestone Pharmaceuticals2.2-0.145-6.18%-- 
Pre Market 2.25 +0.05 +2.27%
Industry overview quotes are at least 15 minutes delayed
Business Description
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.